Case Report | Open Access
Mark Coyle, Mark Wilkinson, Mark Sheehy, "Otherwise Unexplained Transient QTc Prolongation in a Patient Admitted with COVID Disease", Case Reports in Cardiology, vol. 2021, Article ID 9931405, 5 pages, 2021. https://doi.org/10.1155/2021/9931405
Otherwise Unexplained Transient QTc Prolongation in a Patient Admitted with COVID Disease
Background. Several cardiovascular manifestations of coronavirus disease 2019 (COVID-19) have been previously described. QT prolongation has been reported in COVID-19 infection in association with medications such as azithromycin, hydroxychloroquine, and chloroquine but has not previously been reported as a direct result of COVID-19 infection. Case summary. We report the case of a 65-year-old female who developed a prolonged corrected QT interval (QTc) during a hospital admission with COVID-19. This patient was not on any QT prolonging treatment, serum electrolytes were normal, and there was no identifiable reversible cause for the QTc lengthening. Daily serial ECGs during admission showed resolution of the ventricular repolarization abnormality in synchronization with resolution of her COVID-19 viral illness. Discussions. Although there have been reports of QTc prolongation in COVID-19 patients, previous reports of this are for patients receiving medication that causes QT prolongation. This case uniquely demonstrates the development and resolution of this temporary ventricular repolarization abnormality in a patient with a structurally normal heart with no evidence of myocardial fibrosis or edema on cardiac MRI, that is unexplained by other confounding factors, such as medication. This suggests there may be a direct association between COVID-19 and temporary QTc prolongation.
Prolonged QTc is a potentially dangerous ventricular repolarization disorder that can lead to adverse events including torsades de pointes, ventricular fibrillation cardiac arrest, and sudden cardiac death. Causes include both congenital prolongation and acquired causes. Acquired causes include medication, acute electrolyte disturbances, systemic inflammation, and hypoxia [1–3]. There is increasing evidence that inflammatory cytokines, in particular, interleukin 6 (IL-6), can have a direct effect on ventricular cardiomyocyte ion channels, prolonging the action potential and hence the QTc [4–7]. There are few existing case reports of QTc prolongation in patients with COVID in the absence of conventional risk factors [8, 9]. This case suggests there may be an association with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and temporary QTc prolongation.
2. Case Presentation
We report the case of a 65-year-old Caucasian female referred to hospital by her general practitioner with dyspnoea, chest pain, and general malaise, following a recent diagnosis of COVID-19 in the community two days prior to presenting. She had a 5-day history of dyspnoea on exertion and orthopnoea. This was associated with intermittent pleuritic chest pain and fevers. Her medical history included breast cancer treated with a lumpectomy, chemotherapy, and radiotherapy. There was no family history of sudden cardiac death or sudden adult death syndrome, no family history of long QT syndrome, and no family history of congenital deafness. She was not on any QT-prolonging treatment or any rate-limiting therapy, and her only regular medication was rosuvastatin. Her physical examination on presentation was unremarkable. Laboratory investigations revealed a mildly elevated troponin I of 0.06 ng/mL (normal range 0–0.04 ng/mL) which remained at 0.06 ng/mL on serial checking and a D-dimer of 624 ng/mL. Inflammatory markers were normal on admission with a C-reactive protein (CRP) of 7 mg/L (reference range 0.1–5 mg/L) and a white cell count (WCC) of . Her lymphocyte count was . IL-6 levels were not measured. Radiological investigations on admission revealed a normal chest X-ray, and a CT pulmonary angiogram showed patchy peripheral pulmonary infiltrates with no pulmonary embolus. Her admission ECG showed sinus bradycardia with a heart rate of 47 beats per minute and a QTc of 495 ms, shown in Figure 1. QT intervals and RR intervals were measured manually for the calculation of the QTc using Bazett’s method; the calculated values were consistent with the automatic machine measurements.
A repeat ECG one day postadmission showed a QTc of 621 ms, shown in Figure 2. She was commenced on telemetry with daily monitoring of electrolytes and ECGs. Her serum electrolytes were within normal limits throughout the course of the admission. Medications used throughout the admission included enoxaparin and rosuvastatin regularly and paracetamol, lactulose, and cyclizine as required. Cetirizine was subsequently prescribed after the first week of admission. A cardiac MRI was booked in an external centre, and the patient remained in our hospital until she became noninfectious from COVID-19 prior to transfer for MRI. Her QTc decreased gradually over the course of her 24-day hospital admission. From a respiratory perspective, she remained well, her peripheral oxygen saturation levels were normal throughout the entire admission, and she did not develop any supplementary oxygen requirement. Transthoracic echocardiogram was unremarkable, revealing a structurally normal heart and no evidence of heart failure. Cardiac MRI confirmed a structurally normal heart with no evidence of myocardial fibrosis or edema. A trivial pericardial effusion was present. Her QTc resolved to a normal level of 445 ms, shown in Figure 3. She remained clinically well and was discharged.
The average QTc in healthy persons after puberty is milliseconds. Generally, the 99th percentile QTc values are 470 milliseconds in postpubertal males and 480 milliseconds in postpubertal females . A milliseconds is considered highly abnormal for both males and females. Several manifestations of cardiovascular disease have been previously described in COVID-19 . Existing literature regarding QTc prolongation in COVID-19 focuses on predictable pharmacodynamic effects of offlicense pharmacotherapeutic strategies such as antimalarial drugs . The prolongation previously seen has been attributable to medications with this known effect [13, 14]. This case demonstrates an acute ventricular repolarization abnormality in the setting of COVID-19 infection, that self-resolved as the viral illness course resolved. This self-limiting temporary disturbance, in the absence of alternative explanations, suggests that there may be a direct effect on ventricular repolarization from COVID-19. Cetirizine, an anti-H1 histamine receptor drug, was prescribed following a week of admission, which is recognized to have QT-prolonging potential . It is possible that the effects of COVID-associated systemic inflammation on the QTc may have been enhanced by the concomitant cetirizine treatment.
The relationship between COVID-19 and ventricular repolarization is an area of worldwide interest with an ongoing trial in critically unwell patients to determine the effect of COVID-19 (and its treatments) on ventricular repolarization as measured by the QTc . Systemic inflammation rapidly induces cytokine-mediated ventricular electrical remodeling and significant QTc prolongation [17, 18]. It is possible that an important factor involved in QTc prolongation in COVID-19 is the systemic inflammation characterizing the disease, often described as a “cytokine storm” in which IL-6 seems to play a central role. This systemic inflammation via elevated IL-6 is itself an independent risk factor for QTc prolongation, by modulating cardiomyocyte ion channel expression . Other viral illnesses have been reported to exhibit this effect—HIV seropositivity is associated with a prolonged QT . Physiological changes in acute illness can also lead to a temporary ventricular repolarization abnormality—core body temperature can impact QT duration with moderate hypothermia causing temporary prolongation of the QTc as well as fever [20, 21]. However, in this case, our patient remained normothermic throughout the admission, and her CRP and WCC were only very mildly elevated while these electrocardiographic changes occurred, as shown in Table 1. Although CRP synthesis is largely dependent on direct hepatocyte stimulation by IL-6, it is possible for a mismatch to exist (for example, in patients with abnormal liver function) between circulating levels of IL-6 and CRP. Despite this patient having a normal liver function, it cannot be excluded that the blood concentration of IL-6 (which is the actual mediator of the electrophysiologic effects of systemic inflammation on the cardiomyocyte) was higher than expected based on the CRP levels. However, this case suggests that there may be a novel COVID-19 infection-specific mechanism for QT prolongation not previously described.
CRP: C-reactive protein; mg/L: milligrams per liter; WCC: white cell count, QTc: QT interval corrected; ms: milliseconds.
Background information is available on medical database Pubmed.
Written informed consent was obtained from the patient.
Conflicts of Interest
The authors declare no conflict of interest.
- E. Vandael, B. Vandenberk, J. Vandenberghe, R. Willems, and V. Foulon, “Risk factors for QTc-prolongation: systematic review of the evidence,” International Journal of Clinical Pharmacy, vol. 39, no. 1, pp. 16–25, 2017.
- P. E. Lazzerini, M. Boutjdir, and P. L. Capecchi, “COVID-19, arrhythmic risk, and inflammation,” Circulation, vol. 142, no. 1, pp. 7–9, 2020.
- P. Dherange, J. Lang, P. Qian et al., “Arrhythmias and COVID-19: a review,” JACC: Clinical Electrophysiology, vol. 6, no. 9, pp. 1193–1204, 2020.
- P. E. Lazzerini, F. Laghi-Pasini, M. Boutjdir, and P. L. Capecchi, “Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies,” Nature Reviews Immunology, vol. 19, no. 1, pp. 63-64, 2019.
- A. S. Aromolaran, U. Srivastava, A. Alí et al., “Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation,” PLoS One, vol. 13, no. 12, article e0208321, 2018.
- P. E. Lazzerini, F. Laghi-Pasini, I. Bertolozzi et al., “Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes,” Heart, vol. 103, no. 22, pp. 1821–1829, 2017.
- P. E. Lazzerini, P. L. Capecchi, N. El-Sherif, F. Laghi-Pasini, and M. Boutjdir, “Emerging arrhythmic risk of autoimmune and inflammatory cardiac channelopathies,” Journal of the American Heart Association, vol. 7, no. 22, article e010595, 2018.
- B. K. Anupama, S. Adhikari, and D. Chaudhuri, “Prolonged QT interval in a patient with Coronavirus disease-2019: beyond hydroxychloroquine and azithromycin,” Journal of Investigative Medicine High Impact Case Reports, vol. 8, 2020.
- O. Elsaid, P. A. McCullough, K. M. Tecson, R. S. Williams, and A. Yoon, “Ventricular fibrillation storm in coronavirus 2019,” The American Journal of Cardiology, vol. 135, pp. 177–180, 2020.
- J. R. Giudicessi, P. A. Noseworthy, P. A. Friedman, and M. J. Ackerman, “Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19),” in Mayo Clinic Proceedings, pp. 1213–1221, Elsevier, 2020.
- M. Nishiga, D. W. Wang, Y. Han, D. B. Lewis, and J. C. Wu, “COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives,” Nature Reviews Cardiology, vol. 17, no. 9, pp. 543–558, 2020.
- F. Bessière, H. Roccia, A. Delinière et al., “Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit,” JAMA Cardiology, vol. 5, no. 9, pp. 1067–1069, 2020.
- N. J. Mercuro, C. F. Yen, D. J. Shim et al., “Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19),” JAMA Cardiology, vol. 5, no. 9, pp. 1036–1041, 2020.
- S. Agstam, A. Yadav, M. P. Kumar, and A. Gupta, “Hydroxychloroquine and QTc prolongation in patients with COVID-19: a systematic review and meta-analysis,” Indian Pacing and Electrophysiology Journal, vol. 21, no. 1, pp. 36–43, 2021.
- E. Poluzzi, E. Raschi, B. Godman et al., “Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe,” PLoS One, vol. 10, no. 3, article e0119551, 2015.
- M. Zaballos, “Effects on the Qt interval of COVID-19 coronavirus infection (QT-COVID-19),” https://clinicaltrials.gov/ct2/show/study/NCT04422535.
- P. E. Lazzerini, M. Acampa, F. Laghi-Pasini et al., “Cardiac arrest risk during acute infections: systemic inflammation directly prolongs QTc interval via cytokine-mediated effects on potassium channel expression,” Circulation. Arrhythmia and Electrophysiology, vol. 13, no. 8, article e008627, 2020.
- K. C. Wu, L. Zhang, S. A. Haberlen et al., “Predictors of electrocardiographic QT interval prolongation in men with HIV,” Heart, vol. 105, no. 7, pp. 559–565, 2019.
- D. B. Chastain, M. P. Veve, and J. L. Wagner, “Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors,” Antiviral Therapy, vol. 24, no. 6, pp. 459–465, 2019.
- E. S. Dietrichs, T. Tveita, and G. Smith, “Hypothermia and cardiac electrophysiology: a systematic review of clinical and experimental data,” Cardiovascular Research, vol. 115, no. 3, pp. 501–509, 2019.
- A. Burashnikov, W. Shimizu, and C. Antzelevitch, “Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT conditions,” Circulation: Arrhythmia and Electrophysiology, vol. 1, no. 3, pp. 202–208, 2008.
Copyright © 2021 Mark Coyle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.